Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Meet Our Doctors
Dr. Jeffrey Weber
Melanoma Diagnosis Our Approach to Melanoma Treatment
Diagnosis
Melanoma Diagnosis
Surgery
Melanoma Surgery
Targeted Drugs & Immunotherapy
Melanoma Targeted Drugs and Immunotherapy
Radiation Therapy
Melanoma Radiation Therapy

Related News

NYU Langone Receives Grant for Melanoma Research
Read Story
Blood Test to Measure Effectiveness of Skin Cancer Treatment
Read Story
Treatment Options for Later-Stage Melanoma
Read Story
Investigators Develop Novel Blood Tests for Tumor DNA
Read Story
How a Mentor–Mentee Team Found a New Understanding of Cancer
Read Story
Cancer Experts Share Updates in Immunology Advances
Read Story
Expert Discusses Taking Care of Your Skin This Summer
Read Story
Immunotherapy Provides New Options for Advanced Cancers
Read Story
Doctors Define Surgical Margins for Removing Skin Moles
Read Story
New Immunotherapy Drug More Effective in Treating Melanoma
Read Story
Viagra-Like Drugs Not Linked to Skin Cancer, Study Finds
Read Story
Screening Guidelines for Skin Cancer & Melanoma, Explained
Read Story

Clinical Trials and Research Studies

Phase 2

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (mRNA-4157-P201)

Learn More

Phase 1

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Learn More

Phase 1/2

An Open-Label Multicenter Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Learn More

Phase 3

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized Double-blind Phase 3 Study (KEYNOTE 716)

Learn More
View All Related Clinical Trials (19)